Saakshi Medtech & Panels Ltd
SAAKSHISaakshi Medtech & Panels Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting.
The sharpest disagreement: Foreign institutions moved −2.9 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a confirmed uptrend (33 weeks in) while the P/E sits at the 76th percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +500.0% year on year, and 104% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Saakshi Medtech & Panels Ltd trades at ₹345, in a confirmed uptrend and 33 weeks into that stage. That is +40.2% against its own 200-day average. It sits at 100% of a 52-week range of ₹231 to ₹345. On relative strength it has been ahead of the NIFTY 500 on a trailing-13-week view for 7 straight weeks.
Today the stock is in a confirmed uptrend — week 33 of stage 2, confirmed. At ₹345 it trades +40.2% versus its 200-day average and sits at 100% of its 52-week range (₹231–₹345).
Against the market, two honest reads. Cumulative: over the last 4 months the stock moved +28% while the NIFTY 500 moved +1% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 7 straight weeks — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Story check
Saakshi Medtech & Panels Ltd's story is not scored yet against the markers our research file set on 19 July 2026. Where it sits in its own cycle: Not stated in the research file. Still open: If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated.
Our read, 19 July 2026. Saakshi has recovered from the FY25 margin trough, while aerospace, the integrated facility and heat exchangers offer growth paths; thin reporting history, working-capital intensity and conflicting management visibility cap conviction.
From the numbers. The earnings and margin recovery places the business in an early expansion read, but the observed margin history is short and the current valuation is not a clear deep-value entry.
From the price. Price stage 2, week 33 — above its 200-day line, relative strength rising.
From the research. Saakshi has recovered from the FY25 margin trough, while aerospace, the integrated facility and heat exchangers offer growth paths; thin reporting history, working-capital intensity and conflicting management visibility…
🚨 Where they disagree. The earnings and margin recovery places the business in an early expansion read, but the observed margin history is short and the current valuation is not a clear deep-value entry.
What is proven. Saakshi has recovered from the FY25 margin trough, while aerospace, the integrated facility and heat exchangers offer growth paths; thin reporting history, working-capital intensity and conflicting management visibility cap conviction.
What is not proven yet. If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated.
🚨 What would change our mind. If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated.
Layer 1 read, 19 July 2026 — KEEP. Genuine margin recovery off the FY25 trough at a fresh cycle position — but thin history and flat revenue keep it unproven. Operating margin recovered from 8% at the Mar-2025 trough to 20% in Mar-2026 with EPS 0.71 to 3.21, and the price has run only +46% in a year at an AT_TROUGH / EARLY_EXPANSION cycle position. The catch is that this is a small, recently-listed name with roughly seven usable quarters, flat ~57 crore revenue, a still-falling 8-quarter EPS trend, and a single concall that gives conflicting forward guidance. Early and cheap-on-normalized-earnings, but not yet a confirmed growth turn.
What would change Layer 1’s mind. If operating profitability falls back toward the FY25 trough (OPM below ~12%) while inventory and cash absorption continue after facility completion, the recovery is invalidated and this becomes a DROP; conversely, two quarters of rising revenue AND EPS with cleaner order-book disclosure would lift it toward P1.
Layer 2 read, 19 July 2026 — BENCH. Saakshi has the freshest cycle position in the batch — margins recovered from an 8% FY25 trough to 20% and EPS from 0.71 to 3.21, with a regulatory demand-floor tailwind (ALMM). But it carries an EXTREME MoS of -66.9% on flat ~57 cr revenue and only ~7 quarters of history, so this is a margin recovery already discounted, not a proven growth breakout. Externally the sector is CAPACITY_RISK — CWIP +512% with institutions net-selling and the sector timeline calls it a 'peak-margin value-trap risk mid-cycle' — so the recovered margin is structurally exposed.
What would change Layer 2’s mind. If revenue starts growing (not just margins) AND module utilisation climbs back toward the ~65% target so the 20% OPM holds through commissioning, the EXTREME-MoS objection weakens and this flips BENCH->ADVANCE. Conversely operating profit falling back toward the FY25 trough would push it toward DROP.
The test written in advance. If operating profitability falls back toward the FY25 trough while inventory and cash absorption continue after facility completion, the recovery thesis would be invalidated. — the thesis as written as stated by the next result.
The test written in advance. Working-capital and cash absorption — Working-capital and cash absorption Operating cash flow remains below reported net profit after facility completion. by the next result.
The test written in advance. Disclosure inconsistency — Disclosure inconsistency The next call supplies a reconciled backlog, asset-utilisation and revenue bridge. by the next result.
What the company does. The reported FY26 recovery followed the FY25 trough and retained higher operating profitability in the latest reported period. Aerospace production, facility consolidation and radiators offer several growth paths, but customer conversion remains unproven in the reported data. Cash remains tied up in expansion and working capital, while the supplied consistency analysis identifies conflicts in forward disclosure.
| Dial | Now | Was | Why it matters | Watch line |
|---|---|---|---|---|
| Aerospace production and qualification | MEDIUM | — | Aerospace moved from qualification work into serial production, with further customer onboarding under way. | Existing aerospace production does not grow and additional customer qualifications do not convert into production orders. |
| Integrated facility consolidation | MEDIUM | — | The new facility can combine operations, remove rental expense and support higher-value manufacturing. | The facility does not reduce operating friction or requires additional debt-funded capex beyond the stated remaining work. |
| Radiator and heat-exchanger opportunity | MEDIUM | — | Radiators can diversify revenue once facility capacity and customer orders convert. | Customer order conversion remains delayed after facility capacity becomes available. |
🚨 What the surface reading misses. The surface reading is: The annual recovery suggests profitability has moved beyond the FY25 trough. The research reads it further: The higher margin coincides with revenue recovery and management's cost-control explanation, but the available margin series is short and facility depreciation has not yet been tested.
🚨 What the surface reading misses. The surface reading is: Operating cash flow improved in the latest year. The research reads it further: The company is still spending on expansion, so improved operating cash flow has not yet translated into free cash generation.
Sources: our stock research file (19 July 2026) · quarterly results through Mar 26 · the company’s own earnings calls. The story check is re-scored every results season; the record below never changes.
| Section | Where it is now | Vs a year ago | The one thing to watch next | Read |
|---|---|---|---|---|
| Capex | see the section | — | Radiator and heat-exchanger opportunity |
Revenue Revenue is the top line: everything the company billed its customers in the period.
Saakshi Medtech & Panels Ltd reported ₹57.0 Cr of revenue in the Mar 26 quarter, +18.8% year on year. That is the 2nd straight quarter of year-on-year growth. Over 6 years it has compounded at 11.3% a year. The last full year, FY26, came in at ₹116 Cr. The last four reported quarters add to ₹207 Cr.
FY26 revenue came in at ₹116 Cr (+26.1% on the year), capping 6 years at 11.3% compound. The latest quarter (Mar 26) printed ₹57.0 Cr, +18.8% year on year — the 2nd consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +0.3% growth against the decade's 11.3% — the current year is running slower than its own long-run rate.
FY26-Q2. revenue ₹58 Cr and profit ₹7 Cr as reported.
FY26-Q4. revenue ₹57 Cr and profit ₹6 Cr as reported.
Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Saakshi Medtech & Panels Ltd's operating margin is 20.0% in the Mar 26 quarter, +12.0 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across the last four quarters the operating margin has moved +3.0 percentage points.
The latest quarter's operating margin is 20.0%, +12.0 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 10.0%–19.0%, and FY26's 19.0% is the top of that band — a record year.
Why the margin moved: operating margin went +3.6 pp year on year while gross margin went +7.7 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
FY26-Q2. revenue ₹58 Cr and profit ₹7 Cr as reported.
FY26-Q4. revenue ₹57 Cr and profit ₹6 Cr as reported.
Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Saakshi Medtech & Panels Ltd earned ₹6.0 Cr of net profit in the Mar 26 quarter, +500.0% year on year. It is the 2nd consecutive quarter of growth. Full-year FY26 profit was ₹12.0 Cr. The 6-year compound rate is 12.2%. That is 10.5% of the quarter's revenue. The same quarter a year earlier earned ₹6.0 Cr.
Mar 26 profit was ₹6.0 Cr, +500.0% year on year — the 2nd consecutive quarter of growth. On the full year, FY26 printed ₹12.0 Cr (+140.0%), and the 6-year compound rate is 12.2%.
Why profit moved: revenue contributed +18.8% and the margin +12.0 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +125.0% vs revenue +0.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
FY26-Q2. revenue ₹58 Cr and profit ₹7 Cr as reported.
FY26-Q4. revenue ₹57 Cr and profit ₹6 Cr as reported.
Why-sources: our stock research file (19 July 2026) and the company’s own results for those quarters.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 104% of Saakshi Medtech & Panels Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹18.0 Cr of operating cash against ₹12.0 Cr of profit. After ₹25.0 Cr of capital spending, ₹−7.0 Cr was left as free cash.
FY26: operating cash of ₹18.0 Cr against reported profit of ₹12.0 Cr, leaving free cash of ₹−7.0 Cr after ₹25.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 104% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 104%: the cash cycle stretched 56 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 5.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Saakshi Medtech & Panels Ltd's cash conversion cycle runs 144 days in FY26, up from 88 days in FY21. Capital spending ran ₹72.0 Cr over the last 3 years. At FY26 sales of ₹116 Cr each day of that cycle holds about ₹0.3 Cr, so roughly ₹46.0 Cr sits inside the business at any moment.
Why this happened. Management linked the radiator opportunity to the expanded facility and customer execution. It remains a prospective rather than reported source of earnings.
FY26: debtors at 83 days, inventory at 122 days — roughly 4.0 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 144 days, looser than FY21's 88.
The full loop: cash goes out to suppliers and production on day 0; stock waits 122 days to sell; customers pay about 83 days after that; and suppliers themselves are paid at 60 days — netting out to the 144-day cycle.
In money terms: at FY26 sales of ₹116 Cr, each day of the cycle holds about ₹0.3 Cr — so the 144-day loop keeps roughly ₹46.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹72.0 Cr over the last 3 fiscal years against ₹13.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹10.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Saakshi Medtech & Panels Ltd earns a ROCE of 14% in FY26. That is up from a trough of 6% in FY25. Return on invested capital clears the cost of that capital by −2.4 percentage points, so growth here is not yet paying for the capital it uses. The wiring behind it is 10.3% net margin on 0.74× asset turns.
FY26 ROCE is 14%, recovered from a FY25 trough of 6% — the full ladder below shows the fall and the climb, undoctored.
🚨 Why the return is what it is — the wiring (FY26): 10.3% net margin × 0.74× asset turns × 1.41× balance-sheet leverage ≈ 10.7% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 9.6% − 12.0% = a −2.4 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. Negative — growth at these returns destroys value until the returns recover.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Saakshi Medtech & Panels Ltd carries ₹25.0 Cr of borrowings against ₹111 Cr of equity in FY26, a debt-to-equity of 0.23. Operating profit covers the interest bill 22×. Over 5 years borrowings went from ₹22.0 Cr to ₹25.0 Cr. Capital spending ran ₹72.0 Cr across the last 3 of those years.
FY26: borrowings of ₹25.0 Cr against equity of ₹111 Cr — a debt-to-equity of 0.23. Operating profit covers the interest bill 22×. Over 5 years borrowings went from ₹22.0 Cr to ₹25.0 Cr while capital spending ran ₹72.0 Cr in just the last 3 — part of the build-out is riding on borrowed money.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 6.2 points of Saakshi Medtech & Panels Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 0.3% of the company. Foreign institutions moved −2.9 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −6.2 points over 8 quarters to 0.3%; Foreign institutions: −2.9 points over 8 quarters to 0.1%; Promoters: +1.2 points over 8 quarters to 74.8%.
🚨 Why the register moved: domestic institutions drove it (−6.2 points), alongside foreign institutions (−2.9 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Saakshi Medtech & Panels Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Saakshi Medtech & Panels Ltd trades at 49.6× P/E, at the pricey end of its own range (76th percentile). Its long-run median P/E is 40.6×, measured across 2.3 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 49.6× is at the pricey end of its own range (76th percentile), against a long-run median of 40.6× measured over 2.3 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Saakshi Medtech & Panels Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 5 quarters across 1 curve, on partial evidence.
Why it matters: with too little history, an honest page says so instead of guessing a trajectory.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +26.1% | −1.7% | +14.1% | — |
| Profit | +140.0% | +0.0% | +43.1% | — |
| EPS | +160.7% | — | — | — |
4-Factor Sector Score
53.6/100 — rank 13 of 13 in Electric Equipment - General · 41% evidence confidence · provisional, ranked below fully-evidenced peers
Saakshi Medtech & Panels Ltd scores 53.6 out of 100 against the 13 companies it is compared with in Electric Equipment - General, ranking 13. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.
The four contributions add to the total exactly: 20.4 + 12.3 + 9.5 + 11.4 = 53.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Said versus delivered
What Saakshi Medtech & Panels Ltd's management promised, set against what actually arrived — 3 tracked promises on the record. Read straight from the company’s own earnings calls. A promise that slipped stays on this page after it is met.
Conflicting Revenue Potential from Asset Base · 28 November 2025. Within the same November 2025 call, management provided starkly contradictory statements on the company's revenue potential from its asset base. The CFO stated a potential of 150 crores, which was shortly thereafter contradicted by the MD who claimed a potential of 500 crores, creating significant uncertainty about the company's true capacity and internal alignment. Earlier call (Nov 2025): “The potential revenue from the assets is at around 150 crores.” Later call (Nov 2025): “my estimation is that with that kind of a gross block coming in, we should be close to around 500 crores of revenue realization is something that we would be in a position to target.”
Inconsistent FY26 Revenue Outlook · 28 November 2025. Management gave conflicting signals regarding the full-year revenue outlook for FY26 within the November 2025 call. Initially, the MD implied circa 125 crores for the full year by guiding for a typical 15% H2-over-H1 growth. Later in the same call, management endorsed an analyst's figure of 140 crores, creating a material 15 crore gap without explanation. Earlier call (Nov 2025): “typically there is a close to around 15% growth which we see between H1 and H2. We don”. Later call (Nov 2025): “We should be somewhere close to that.”
Contradictory Statements on Order Book Visibility · 28 November 2025. In the November 2025 call, management's statements on order book visibility were contradictory. The MD initially claimed the company has 'only a three-month visibility' for its order book. However, later in the call, he detailed a specific '230 odd crores of order book is yet to be executed over the next four years' for a single customer, directly contradicting the earlier assertion of limited forward visibility. Earlier call (Nov 2025): “typically we have only a three-month visibility in terms of what is the order book that is available with us.” Later call (Nov 2025): “Close to around 230 odd crores of order book is yet to be executed over the next four years.”
Every quote above is taken word for word from the company’s own earnings calls.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1Emmvee Photovoltaic Power LtdEMMVEE | 72.9/100Favorable setup73% evidence | FADING | 29.4/35 Revenue 84.1% · PAT 100% · OPM change 1 pp 100% evidence | 18.8/25 ROCE 44.8% · OPM 35% 100% evidence | 14.7/20 P/E 18.8× · PEG 0.92 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y —9 of 12 weeks ahead 0% evidence |
| Exact sum: 29.4 + 18.8 + 14.7 + 10 = 72.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 2Fujiyama Power Systems LtdUTLSOLAR | 55.4/100Mixed-positive evidence63% evidence | BREAKING OUT | 21.8/35 Revenue 95% · PAT 62.4% · OPM change 1 pp 100% evidence | 13.6/25 ROCE 29.4% · OPM 19% 100% evidence | 10.0/20 P/E 32.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 21.8 + 13.6 + 10 + 10 = 55.4 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Hindusthan Insulators & Industries Ltd539984 | 53.2/100Mixed-positive evidence67% evidence | TURNING | 23.9/35 Revenue 41.8% · PAT 100% · OPM change 32 pp 71% evidence | 7.3/25 ROCE 10.6% · OPM 38% 76% evidence | 11.0/20 P/E 13.5× · PEG — 15% evidence | 11.0/20 RS sector -39.3% · RS bench 81.1% · 1Y -1.3%2 of 12 weeks ahead 100% evidence |
| Exact sum: 23.9 + 7.3 + 11 + 11 = 53.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Indosolar LtdWAAREEINDO | 50.2/100Mixed-positive evidence74% evidence | ASLEEP | 13.0/35 Revenue 7% · PAT -5.7% · OPM change 38 pp 95% evidence | 19.8/25 ROCE 124% · OPM 71% 95% evidence | 11.5/20 P/E 6.3× · PEG — 15% evidence | 5.9/20 RS sector -6.5% · RS bench -41.1% · 1Y -42.4%0 of 10 weeks ahead 70% evidence |
| Exact sum: 13 + 19.8 + 11.5 + 5.9 = 50.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5ABB India LtdABB | 46.3/100Mixed-negative evidence74% evidence | BREAKING OUT | 17.4/35 Revenue 10.2% · PAT 66.5% · OPM change -1 pp 71% evidence | 14.8/25 ROCE 29.9% · OPM 13% 76% evidence | 6.8/20 P/E 100× · PEG — 50% evidence | 7.3/20 RS sector -19.2% · RS bench 18.5% · 1Y 42.1%5 of 12 weeks ahead 100% evidence |
| Exact sum: 17.4 + 14.8 + 6.8 + 7.3 = 46.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Saatvik Green Energy LtdSAATVIKGL | 45.2/100Mixed-negative evidence73% evidence | ASLEEP | 7.7/35 Revenue 46.5% · PAT -21.9% · OPM change -12.7 pp 100% evidence | 12.0/25 ROCE 32.9% · OPM 6.6% 100% evidence | 15.5/20 P/E 20.2× · PEG 0.65 65% evidence | 10.0/20 RS sector — · RS bench — · 1Y -10.2%1 of 12 weeks ahead 0% evidence |
| Exact sum: 7.7 + 12 + 15.5 + 10 = 45.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 7Vidya Wires LtdVIDYAWIRES | 43.5/100Mixed-negative evidence60% evidence | TURNING | 14.5/35 Revenue 31.6% · PAT 40.9% · OPM change -0.5 pp 95% evidence | 8.8/25 ROCE 20.6% · OPM 4% 95% evidence | 10.2/20 P/E 30× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —4 of 12 weeks ahead 0% evidence |
| Exact sum: 14.5 + 8.8 + 10.2 + 10 = 43.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Yash Highvoltage Ltd544310 | 59.4/100Thin evidence · provisional47% evidence | LEADER | 18.4/35 Revenue — · PAT — · OPM change 3 pp 14% evidence | 15.4/25 ROCE 28.6% · OPM 26% 76% evidence | 8.7/20 P/E 72.6× · PEG — 15% evidence | 16.9/20 RS sector 10.2% · RS bench 55.2% · 1Y 86.8%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 15.4 + 8.7 + 16.9 = 59.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Vivid Electromech LtdVIVIDEL | 56.9/100Thin evidence · provisional34% evidence | BREAKING OUT | 17.0/35 Revenue — · PAT — · OPM change 4 pp 19% evidence | 20.9/25 ROCE 58.6% · OPM 24% 95% evidence | 9.0/20 P/E 54.9× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —8 of 8 weeks ahead 0% evidence |
| Exact sum: 17 + 20.9 + 9 + 10 = 56.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10GP Eco Solutions India LtdGPECO | 56.1/100Thin evidence · provisional41% evidence | 20.5/35 Revenue — · PAT — · OPM change 10 pp 26% evidence | 16.3/25 ROCE 38.3% · OPM 15% 95% evidence | 11.3/20 P/E 11.9× · PEG — 15% evidence | 8.0/20 RS sector — · RS bench -10.2% · 1Y —4 of 4 weeks ahead to 2026-08-09 25% evidence | |
| Exact sum: 20.5 + 16.3 + 11.3 + 8 = 56.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Parth Electricals & Engineering LtdPARTH | 53.7/100Thin evidence · provisional50% evidence | LEADER | 16.6/35 Revenue — · PAT — · OPM change 1 pp 26% evidence | 11.3/25 ROCE 21% · OPM 9% 95% evidence | 9.3/20 P/E 51.3× · PEG — 15% evidence | 16.5/20 RS sector 14.7% · RS bench 61.7% · 1Y 99.8%12 of 12 weeks ahead 70% evidence |
| Exact sum: 16.6 + 11.3 + 9.3 + 16.5 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Indo SMC Ltd544681 | 53.7/100Thin evidence · provisional31% evidence | BREAKING OUT | 17.4/35 Revenue — · PAT — · OPM change 4 pp 26% evidence | 16.5/25 ROCE 33.9% · OPM 15% 76% evidence | 9.8/20 P/E 37.3× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —12 of 12 weeks ahead 0% evidence |
| Exact sum: 17.4 + 16.5 + 9.8 + 10 = 53.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 13Saakshi Medtech & Panels Ltdthis pageSAAKSHI | 53.6/100Thin evidence · provisional41% evidence | BREAKING OUT | 20.4/35 Revenue — · PAT — · OPM change 12 pp 26% evidence | 12.3/25 ROCE 14.3% · OPM 20% 95% evidence | 9.5/20 P/E 49.6× · PEG — 15% evidence | 11.4/20 RS sector — · RS bench 59.4% · 1Y —5 of 6 weeks ahead 25% evidence |
| Exact sum: 20.4 + 12.3 + 9.5 + 11.4 = 53.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Saakshi Medtech & Panels Ltd's share price today?
Saakshi Medtech & Panels Ltd trades at ₹345. The company is valued at ₹610 Cr. The stock sits at the very top of its 52-week range (₹231–₹345), +40.2% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 33 weeks in. — as of 11 September 2026.
What were Saakshi Medtech & Panels Ltd's latest quarterly results?
Saakshi Medtech & Panels Ltd reported revenue of ₹57.0 Cr and net profit of ₹6.0 Cr for the Mar 26 quarter. Revenue rose 18.8% and profit rose 500.0% year on year. Earnings per share were ₹3.21. The operating margin was 20.0%, 12.0 pp higher than a year earlier. — as of 11 September 2026.
What is Saakshi Medtech & Panels Ltd's revenue?
Saakshi Medtech & Panels Ltd reported revenue of ₹57.0 Cr in the Mar 26 quarter, +18.8% year on year. For the full FY26 fiscal year, revenue was ₹116 Cr (+26.1%). Over the last 6 years revenue compounded at 11.3% a year. — as of 11 September 2026.
What is Saakshi Medtech & Panels Ltd's profit?
Saakshi Medtech & Panels Ltd earned ₹6.0 Cr of net profit in the Mar 26 quarter, +500.0% year on year — the 2nd straight quarter of growth. Full-year FY26 profit was ₹12.0 Cr. The operating margin ran 20.0% in the latest quarter. — as of 11 September 2026.
What is Saakshi Medtech & Panels Ltd's market cap?
Saakshi Medtech & Panels Ltd's market capitalisation is ₹610 Cr at a share price of ₹345. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 11 September 2026.
What is Saakshi Medtech & Panels Ltd's P/E ratio?
Saakshi Medtech & Panels Ltd trades at a P/E of 49.6×, at the 76th percentile of its own 2-year range, against a long-run median of 40.6×. This is a comparison with the stock's own history, not a value call — as of 11 September 2026.
Does Saakshi Medtech & Panels Ltd pay a dividend?
No — Saakshi Medtech & Panels Ltd has recorded a dividend payout of 0% of profit in each of its last 7 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 11 September 2026.
Is Saakshi Medtech & Panels Ltd overvalued?
On its own history, Saakshi Medtech & Panels Ltd looks expensive: its P/E of 49.6× sits at the 76th percentile of its 2-year range (long-run median 40.6×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 11 September 2026.
Is Saakshi Medtech & Panels Ltd growing?
Yes — Saakshi Medtech & Panels Ltd is growing: latest-quarter revenue +18.8% year on year, profit +500.0%, and the margin +12.0 pp at 20.0%. The 6-year compound rates are 11.3% (revenue) and 12.2% (profit). The earnings engine currently reads: improving — as of 11 September 2026.
How is Saakshi Medtech & Panels Ltd performing?
Saakshi Medtech & Panels Ltd is in a confirmed uptrend, 33 weeks in. Its latest quarter's revenue rose 18.8% and profit rose 500.0% year on year. Against the NIFTY 500 it has been ahead on a trailing-13-week view for 7 weeks. This describes what the data did, not a rating. — as of 11 September 2026.
Is Saakshi Medtech & Panels Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 33 of stage 2), trading +40.2% versus its 200-day average and at the very top of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 11 September 2026.
Is Saakshi Medtech & Panels Ltd beating the market?
On recent form, yes — Saakshi Medtech & Panels Ltd has been ahead of the NIFTY 500 on a trailing-13-week view for 7 straight weeks, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 4 months the stock moved +28% against the NIFTY 500's +1% — ahead of the index over the full window. — as of 11 September 2026.
Will Saakshi Medtech & Panels Ltd's share price go up?
This page publishes no price forecast for Saakshi Medtech & Panels Ltd. What it measures instead: the share price is ₹345, the price is in a confirmed uptrend 33 weeks in. Its P/E of 49.6× sits at the 76th percentile of its own 2-year range. — as of 11 September 2026.
Who owns Saakshi Medtech & Panels Ltd?
Promoters hold 74.8% of Saakshi Medtech & Panels Ltd, foreign institutions 0.1%, domestic institutions 0.3% and the public 24.8% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 6.2 points over 8 quarters. — as of 11 September 2026.
Does Saakshi Medtech & Panels Ltd have too much debt?
No — Saakshi Medtech & Panels Ltd's debt-to-equity is 0.23, and operating profit covers the interest bill 22×. FY26 borrowings were ₹25.0 Cr against equity of ₹111 Cr. The returns on this page are earned, not borrowed — as of 11 September 2026.
What is Saakshi Medtech & Panels Ltd's capex?
Saakshi Medtech & Panels Ltd spent ₹72.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹25.0 Cr, with ₹10.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 11 September 2026.
What is Saakshi Medtech & Panels Ltd's cash flow?
Saakshi Medtech & Panels Ltd generated ₹18.0 Cr of operating cash flow in FY26 and ₹−7.0 Cr of free cash flow after ₹25.0 Cr of capital spending. Reported profit that year was ₹12.0 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 11 September 2026.
Is Saakshi Medtech & Panels Ltd's profit real cash?
Yes — over the last 3 fiscal years, 104% of Saakshi Medtech & Panels Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹18.0 Cr against reported profit of ₹12.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 11 September 2026.
Where is Saakshi Medtech & Panels Ltd in its business cycle?
Saakshi Medtech & Panels Ltd's FY26 operating margin was 19.0%, against a 7-year band of 10.0%–19.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 20.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 11 September 2026.
What could break the Saakshi Medtech & Panels Ltd story?
The sharpest disagreement: Foreign institutions moved −2.9 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 11 September 2026.
Is Saakshi Medtech & Panels Ltd a stock worth studying right now?
This is not investment advice. The machine read: Saakshi Medtech & Panels Ltd is printing record margins on a fuller multiple. From here the earnings must do all the lifting. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 11 September 2026.
Not SEBI Registered !! Not Investment advice !!